drugset / Trial / NCT01380366
rHGH and Intestinal Permeability in Intestinal Failure
Phase 4
Completed
15 enrolled
Northwestern University
EMD Serono · collabNorthwestern Memorial Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
Patients who are being asked to participate in this study have a short small bowel and will be prescribed to take the medication: Zorbtive® ("Zorbtive/Somatropin/(rHGH)"). Zorbtive® is an FDA approved recombinant human growth hormone (rHGH). The investigators want to see if taking this medication improves small bowel function by helping it to take in food, nutrients, vitamins and minerals. The investigators also believe that if the small bowel is absorbing food and nutrients better, liver function will improve as well. Therefore, liver function will also be monitored during the course of the study by performing blood tests.
Timeline
- Start
- 2006-10
- Primary completion
- 2011-02
- Completion
- 2015-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Somatropin | Protein / enzyme biologic | 0.1 mg/kg | Subcutaneous |